In this presentation, the speakers will report the results of a series of three population-based cohort studies relating to the use and effects of smoking cessation pharmacotherapies. The first of these studies provides evidence on how the three smoking cessation pharmacotherapies available in Australia (nicotine replacement therapy, varenicline and bupropion) compare to each other in terms of cardiovascular safety.
The objective of this webinar is to support decision-makers who protect effective alcohol regulations by raising awareness of conflicts of interests, summarizing the current evidence on interference from the alcohol industry in public health policy as well as discuss best practices.
